Cancer cells can shut down immune attacks by expressing the PD-L1 (programmed death-ligand 1) on their cell surface and interacting with the PD-1 (programmed cell death protein-1) receptor on tumor-infiltrating lymphocytes, such as the CD8+ cytotoxic T-cells. The gene discussed is PDCD1; the disease is neoplasm.